ABOS EBITDA | Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc. (ABOS) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income -$32.56M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income -$21.15M; Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA (m); Operating income -$26.51M; Depreciation and amortization (m).
2025-06-30: Basis Reported; EBITDA (m); Operating income -$41.75M; Depreciation and amortization (m).

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	-$32.56M	(m)	(m)	(m)	(m)	-$18.07M*	(m)	$27.81M	(m)	(m)
2026-03-31	Reported	(m)	-$21.15M	(m)	(m)	(m)	(m)	-$24.13M	(m)	$16.48M	(m)	(m)
2025-09-30	Reported	(m)	-$26.51M	(m)	(m)	(m)	(m)	-$30.49M*	(m)	$21.97M	(m)	(m)
2025-06-30	Reported	(m)	-$41.75M	(m)	(m)	(m)	(m)	-$31.83M*	(m)	$37.13M	(m)	(m)
2025-03-31	Reported	(m)	-$30.37M	(m)	(m)	(m)	(m)	-$34.12M	(m)	$25.27M	(m)	(m)
2024-09-30	Reported	(m)	-$32.27M	(m)	(m)	(m)	(m)	-$24.60M*	(m)	$27.25M	(m)	(m)
2024-06-30	Reported	(m)	-$24.38M	(m)	(m)	(m)	(m)	-$16.55M*	(m)	$19.53M	(m)	(m)
2024-03-31	Reported	(m)	-$17.77M	(m)	(m)	(m)	(m)	-$17.86M	(m)	$12.45M	(m)	(m)
2023-09-30	Reported	(m)	-$16.04M	(m)	(m)	(m)	(m)	-$12.90M*	(m)	$11.18M	(m)	(m)
2023-06-30	Reported	(m)	-$13.48M	(m)	(m)	(m)	(m)	-$11.67M*	(m)	$9.13M	(m)	(m)
2023-03-31	Reported	(m)	-$13.13M	(m)	(m)	(m)	(m)	-$10.18M	(m)	$8.71M	(m)	(m)
2022-09-30	Reported	(m)	-$11.37M	(m)	(m)	(m)	(m)	-$9.18M*	(m)	$8.31M	(m)	(m)
2022-06-30	Reported	(m)	-$10.41M	(m)	(m)	(m)	(m)	-$6.47M*	(m)	$7.32M	(m)	(m)
2022-03-31	Reported	(m)	-$9.21M	(m)	(m)	(m)	(m)	-$8.30M	(m)	$5.99M	(m)	(m)
2021-09-30	Reported	(m)	-$3.94M	(m)	(m)	(m)	(m)	-$7.69M*	(m)	$1.80M	(m)	(m)
2021-06-30	Reported	(m)	-$3.44M	(m)	(m)	(m)	(m)	-$4.26M*	(m)	$2.25M	(m)	(m)
2021-03-31	Reported	(m)	-$3.79M	(m)	(m)	(m)	(m)	-$2.37M	(m)	$2.58M	(m)	(m)
2020-09-30	Reported	(m)	-$2.49M	(m)	(m)	(m)	(m)	-$1.28M*	(m)	$2.99M	(m)	(m)
2020-06-30	Reported	(m)	-$2.04M	(m)	(m)	(m)	(m)	(m)	(m)	$1.93M	(m)	(m)

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	(m)	-$123.83M	(m)	(m)	(m)	(m)	-$115.54M	(m)	$104.89M	(m)	$0.00
2024-12-31	Reported	(m)	-$114.02M	(m)	(m)	(m)	(m)	-$86.22M	(m)	$93.80M	(m)	$0.00
2023-12-31	Reported	(m)	-$61.14M	(m)	(m)	(m)	(m)	-$43.06M	(m)	$42.32M	(m)	$0.00
2022-12-31	Reported	(m)	-$45.24M	(m)	(m)	(m)	(m)	-$35.15M	(m)	$32.36M	(m)	$0.00
2021-12-31	Reported	(m)	-$19.58M	(m)	(m)	(m)	(m)	-$17.96M	(m)	$12.30M	(m)	$0.00
2020-12-31	Reported	(m)	-$7.91M	(m)	(m)	(m)	(m)	-$7.45M	(m)	$8.00M	(m)	$0.00

Stock Name	Country	Market Cap	PE Ratio
Outlook Therapeutics, Inc. (OTLK)	United States	$0.162B	-4.90
Humacyte, Inc. (HUMA)	United States	$0.155B	-2.26
Voyager Therapeutics, Inc. (VYGR)	United States	$0.173B	-1.99
PRECISION BIOSCIENCES INC (DTIL)	United States	$0.175B	-3.95
Coherus Oncology, Inc. (CHRS)	United States	$0.182B	-1.63
Tenaya Therapeutics, Inc. (TNYA)	United States	$0.140B	-1.60
Alpha Cognition Inc. (ACOG)		$0.185B	-6.77
Caribou Biosciences, Inc. (CRBU)	United States	$0.134B	-1.79
Armata Pharmaceuticals, Inc. (ARMP)	United States	$0.132B
Neumora Therapeutics, Inc. (NMRA)	United States	$0.132B	-1.48